NEW YORK (GenomeWeb) – Bayer CropScience today said that it is investing almost $1 billion in capital expenditures in the US between 2013 and 2016 to build up its R&D capabilities and expand its supply of crop protection brands.

The funding is part of a global investment program that Bayer CropScience began last year with total capital expenditures of €2.4 billion ($3.3 billion) between 2013 and 2016.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.